arrow
F

Francesco Del Galdo

Leeds Institute of Rheumatic and Musculoskeletal Medicine
H指数:40
被引数:6,520

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study

系统性硬化症相关肺动脉高压患者口服抗凝剂的有效性:一项EUSTAR队列研究

2026-09-180
OAAI
Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort

系统性硬化症中JAK抑制剂的实时安全性和有效性:来自EUSTAR队列的倾向性匹配研究

2026-09-080
OAAI
Advances in imaging for systemic sclerosis

系统性硬化症影像学进展

2026-07-310
PRE
Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management

合并症和患者人口统计学特征对雷诺现象症状特征的影响:对诊断和管理的启示

2026-05-260
PRE
Corrigendum to “Targeting Tenascin-C-Toll-like Receptor 4 signalling with Adhiron-derived small molecules - a viable strategy for reducing fibrosis in systemic sclerosis” [Bioorg. Chem. 167 (2025) 109251]

勘误:“Targeting Tenascin-C-Toll-like Receptor 4 signalling with Adhiron-derived small molecules - a viable strategy for reducing fibrosis in systemic sclerosis” [Bioorg. Chem. 167 (2025) 109251]

2025-12-110
OAAI
Targeting tenascin-C-toll-like receptor 4 signalling with Adhiron-derived small molecules - a viable strategy for reducing fibrosis in systemic sclerosis

靶向tenascin-C-toll-like receptor 4信号通路,使用Adhiron衍生的small molecules——一种减轻系统性硬化症纤维化的可行策略

2025-11-150
PRE
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis

利用统一的血管框架来预测器官特异性并发症并实现系统性硬化病的疾病修饰

2025-10-140
PRE
Transforming growth factor beta (TGF-β) induces type 1 interferon signalling in systemic sclerosis keratinocytes through the chloride intracellular channel 4 (CLIC4)

转化生长因子β(TGF-β)通过氯离子通道4(CLIC4)诱导系统性硬化症角化细胞中Ⅰ型干扰素信号通路。

2025-10-030
OAAI
Morphological reprogramming of primary cilia length mitigates the fibrotic phenotype in fibroblasts across diverse fibrotic conditions

原代纤毛长度形态的重编程可减轻多种纤维化条件下的成纤维细胞纤维化表型

2025-10-010
PRE
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis

“我这样做对吗?”——医师对系统性硬化症临床试验中全球评估的看法

2025-09-010
OAAI
Entheseal structural damage according to OMERACT definitions unveils distinct ultrasound phenotypes in SpA: findings from the DEUS multicentre study

根据OMERACT定义的肌腱端结构损伤揭示了SpA中不同的超声表型:DEUS多中心研究的结果

2025-08-280
OAAI
Multimodal ultrasound in the assessment of muscle involvement in systemic sclerosis patients: results from a bicentric study

多模态超声在系统性硬化症患者肌肉受累评估中的应用:一项双中心研究的结果

2025-08-010
OAAI
Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort

系统性硬化症患者血管药物使用的时间趋势:来自EUSTAR队列的见解,以指导未来试验和治疗方案

2025-06-010
PRE
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study

血清I型干扰素评分作为弥漫性皮肤系统性硬化症患者疾病活动性生物标志物:一项回顾性队列研究

2025-03-310
PRE